Norepinephrine Transporter-Targeted Cancer Theranostics-New Horizons

Related Experiment Video

Updated: Jun 7, 2025

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.3K

Takahiro Higuchi, Konrad Klimek1, Daniel Groener1

  • 1Clinic for Radiology and Nuclear Medicine, Department of Nuclear Medicine, Goethe University Frankfurt, University Hospital, Frankfurt, Germany.

Clinical Nuclear Medicine
|November 21, 2024
PubMed

Insights

This review explores radiopharmaceuticals targeting the norepinephrine transporter (NET) for diagnosing and treating NET-expressing tumors like pheochromocytoma. It highlights advanced imaging agents and targeted alpha therapies for precision oncology.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Precision oncology increasingly utilizes targeted therapies.
  • Radiopharmaceuticals targeting the norepinephrine transporter (NET) are crucial for specific neuroendocrine tumors.
  • 123I-MIBG and 131I-MIBG are established agents for diagnosing and treating NET-expressing tumors.

Purpose of the Study:

  • To review the role of NET-targeting radiopharmaceuticals in oncology.
  • To discuss current applications of 123I-MIBG and 131I-MIBG.
  • To highlight novel PET imaging agents and targeted alpha therapies.

Main Methods:

  • Review of current literature on NET-targeting radiopharmaceuticals.
  • Analysis of clinical applications of 123I-MIBG and 131I-MIBG.
  • Discussion of emerging 18F-labeled PET tracers and 211At-MABG therapy.

Main Results:

  • 123I-MIBG offers diagnostic imaging for NET-expressing tumors.
  • 131I-MIBG provides therapeutic options for these tumors.
  • Newer 18F-labeled tracers enhance imaging resolution and tumor localization.
  • 211At-MABG shows promise for targeted alpha-particle therapy.

Conclusions:

  • NET-targeting radiopharmaceuticals are vital in precision oncology.
  • Advancements in PET imaging and alpha-particle therapy offer improved theranostic approaches.
  • These agents hold significant potential for managing pheochromocytoma, neuroblastoma, and paraganglioma.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

324

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K